Subscribe
Podcasts
Clinical Conversations
COVID-19 Webcast Series
Webcast Replays
Webcast Coverage
Faculty
Sponsors
Videos & Articles
About
About AVBCC
Leadership & Co-Chairs
Return to VBCC
Winner of Folio's 2020
Eddie & Ozzie Awards
AVBCC
COVID-19 Webcast Series
Webcast Replays
COVID-19 Impact on the Cancer Care Delivery Ecosystem
LIVE Webcast Series
Webcast Replays
Webcast Coverage
Podcasts
Faculty
Sponsors
Chase Doyle
Authored Articles
Survey of Oncologists Identifies Several Misconceptions Regarding Biosimilars
Chase Doyle
Biosimilars
April 2022, Vol 13, No 2
Read Article
Analysis of Insurance Claims Reveals Upward Trend in the Use of Trastuzumab Biosimilars
Chase Doyle
Biosimilars
April 2022, Vol 13, No 2
Read Article
mRNA COVID-19 Vaccine Appears Safe and Effective in Patients with Cancer Receiving Active Treatment
Chase Doyle
COVID-19
February 2022, Vol 13, No 1 Online Only
Read Article
Pharmacist-Driven Intervention Leads to Significant Increase in Biosimilar Adoption
Chase Doyle
Biosimilars
February 2022, Vol 13, No 1 Online Only
Read Article
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2 Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Chase Doyle
Breast Cancer
October 2021, Vol 12, No 5
Read Article
Daratumumab in Newly Diagnosed Multiple Myeloma: Weighing the Pros and Cons
Chase Doyle
Hematologic Malignancies
October 2021, Vol 12, No 5
Read Article
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
ASCO 2021 Highlights
,
Biosimilars
August 2021, Vol 12, No 4
Read Article
First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma
Chase Doyle
Emerging Therapies
,
Lymphoma
February 2021, Vol 12, No 1
Read Article
Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life
Chase Doyle
Value-Based Care
February 2021, Vol 12, No 1
Read Article
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Chase Doyle
Emerging Therapies
February 2021, Vol 12, No 1
Read Article
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Chase Doyle
Lymphoma
February 2021, Vol 12, No 1
Read Article
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
Chase Doyle
Lymphoma
February 2021, Vol 12, No 1
Read Article
Social Determinants of Health in Cancer Care
Chase Doyle
ASCO Quality Care Symposium
,
Social Determinants
December 2020, Vol 11, No 6
Read Article
New Research Highlights Barriers to Clinical Trial Participation
Chase Doyle
Clinical Trials
December 2020, Vol 11, No 6
Read Article
Innovations in Quality Care During the COVID-19 Pandemic: Lessons Learned
Chase Doyle
ASCO Quality Care Symposium
December 2020, Vol 11, No 6
Read Article
Multidisciplinary Cancer Care Starts and Ends with the Patient
Chase Doyle
ASCO Quality Care Symposium
December 2020, Vol 11, No 6
Read Article
Financial Toxicity Can Be Deadly for Patients with Cancer
Chase Doyle
Value-Based Care
December 2020, Vol 11, No 6
Read Article
FGFR Inhibition in Cholangiocarcinoma and Resistance to Therapy
Chase Doyle
Cholangiocarcinoma
December 2020, Vol 11, No 6
Read Article
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
Chase Doyle
Cholangiocarcinoma
December 2020, Vol 11, No 6
Read Article
Bortezomib, Lenalidomide, and Dexamethasone Remains Standard of Care for Treatment of Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
Multiple Myeloma
October 2020, Vol 11, No 5
Read Article
Clinical Decision Support Helps Compliance with Evidence-Based Pathways
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Cemiplimab Cost-Effective for Advanced Cutaneous Squamous-Cell Carcinoma
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Germline Alterations Analysis Has Actionable Value in Selecting Targetable Treatments for Patients with Advanced Cancer
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
The Value of Some Cancer Drugs Changes Substantially After Their Approval
Chase Doyle
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors
Chase Doyle
Emerging Therapies
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Chase Doyle
Multiple Myeloma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Chase Doyle
Colon Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Leukemia
,
Lymphoma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma
Chase Doyle
Leukemia
,
Lymphoma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML
Chase Doyle
Economics & Value
,
Value-Based Care
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
Chase Doyle
Lymphoma
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia
Chase Doyle
Leukemia
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
Chase Doyle
Breast Cancer
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Delivering High-Value Personalized Interventions
Chase Doyle
Value-Based Care
,
Economics & Value
October 2019, Vol 10, No 5
Read Article
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
Chase Doyle
Clinical Trials
,
Personalized Medicine
October 2019, Vol 10, No 5
Read Article
Financial Toxicity High for Low-Income Patients in Early-Phase Clinical Trials
Chase Doyle
Financial Toxicity
October 2019, Vol 10, No 5
Read Article
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
Chase Doyle
Clinical Pathways
October 2019, Vol 10, No 5
Read Article
Oral Parity Laws Could Reduce Disparities in Cancer Care
Chase Doyle
Disparities in Oncology
October 2019, Vol 10, No 5
Read Article
Patient Navigators, Clinician Education Can Remove Barriers to Enrollment in Clinical Trials
Chase Doyle
Patient Navigation
,
Value-Based Care
,
Personalized Medicine
,
Economics & Value
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia
Chase Doyle
Leukemia
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes
Chase Doyle
Myelodysplastic Syndromes
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
Multiple Myeloma
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia
Chase Doyle
Leukemia
,
Hematologic Malignancies
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
Pancreatic Cancer
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer
Chase Doyle
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
LOXO-292 Highly Effective in RET-Positive Cancers
Chase Doyle
Emerging Therapies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Discussing Costs with Your Patient Can Reduce Financial Toxicity
Chase Doyle
Economics & Value
,
Financial Toxicity
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Stem-Cell Transplant in Multiple Myeloma Associated with Increased Healthcare Utilization and Costs
Chase Doyle
Leukemia
,
Multiple Myeloma
,
Hematologic Malignancies
Web Exclusives
Read Article
Brentuximab Vedotin plus Nivolumab Yields High Complete Responses in Relapsed or Refractory Hodgkin Lymphoma
Chase Doyle
Lymphoma
,
Solid Tumors
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Recent FDA Approvals for ALL a “Watershed” Moment
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Profound Symptom Burden of Myeloproliferative Neoplasms Highlighted in New Studies
Chase Doyle
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden
Chase Doyle
Economics & Value
,
Value-Based Care
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Rapid Adoption of Oncology Drugs Improves Survival
Chase Doyle
Value in Oncology
December 2017, Vol 8, No 5
Read Article
Overcoming Barriers to Cost Transparency in Cancer Care
Chase Doyle
Economics & Value
,
Value-Based Care
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Patients with Curable Cancer Experience Significant Symptom Burden and Hospitalization
Chase Doyle
Economics & Value
,
Value-Based Care
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
Multiple Myeloma
,
Hematologic Malignancies
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Adoptive T-Cell Therapy: Ready for Prime Time
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Oncologists Must Begin to Discuss Financial Toxicity with Patients
Chase Doyle
Value-Based Care
,
Economics & Value
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Induction Therapy plus Autologous Stem-Cell Transplantation Still Cost-Effective for Newly Diagnosed Multiple Myeloma
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
Read Article
BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
Read Article
Increased Utilization of Biosimilars in Oncology Could Save Payers Millions
Chase Doyle
Economics & Value
,
Value-Based Care
,
Biosimilars
February 2017, Vol 8, No 1
Read Article
Value Frameworks Unreliable in Assessing Novel Hematologic Therapies
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
Read Article
Frontline Use of Bendamustine plus Rituximab Cost-Effective for Indolent B-Cell Non-Hodgkin Lymphoma
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
Read Article
ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia
Chase Doyle
Economics & Value
,
Value-Based Care
,
ASCO’s Value Framework
February 2017, Vol 8, No 1
Read Article
Trajectory of Illness and Distress in Patients Undergoing Stem-Cell Transplantation
Chase Doyle
Palliative Care
,
Personalized Medicine
November 2016, Vol 7, No 10
Read Article
Disparities in Rehospitalization Rates Among Patients with Advanced Cancer
Chase Doyle
Palliative Care
,
Personalized Medicine
November 2016, Vol 7, No 10
Read Article
Out-of-Pocket Costs Are High for End-of-Life Care in Patients with Blood Cancers
Chase Doyle
Value in Oncology
November 2016, Vol 7, No 10
Read Article
Palliative Care Program Eases Patient Symptoms and Hospital Costs
Chase Doyle
Value in Oncology
November 2016, Vol 7, No 10
Read Article
Patient-Reported Outcomes Should Be Used Routinely in Cancer Care
Chase Doyle
Palliative Care
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Immunotherapies Changing the Treatment Landscape of Advanced Cancer Care
Chase Doyle
Immunotherapy
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Palliative Care for Caregivers: Implementing Caregiver Support Programs
Chase Doyle
Palliative Care
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Clinical Pathways in Payment Reform Should Address Risk Adjustment
Chase Doyle
Clinical Pathways
September 2016, Vol 7, No 8
Read Article
Referring Radical Prostatectomies to High-Volume Providers Could Save Millions
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
Read Article
Assessing the Cost–Benefit of Immune Checkpoint Inhibitors
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
Read Article
Value Frameworks in Oncology: Economic Analyses of 4 Clinical Interventions
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
Read Article
How to Reduce Financial Toxicity in Patients with Cancer
Chase Doyle
Financial Toxicity
,
Value in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Transition from Branded to Generic Cancer Drugs Significantly Increases Treatment Cost-Effectiveness
Chase Doyle
Value in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Out-of-Pocket Costs Linked to Reduced Adherence to Oral Oncolytics
Chase Doyle
Value in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Opportunities for Shared Decision-Making in Clinical Practice
Chase Doyle
Value in Oncology
July 2016, Vol 7, No 6
Read Article
Imatinib Can Be Safely Discontinued in Patients with Deep Molecular Response
Chase Doyle
Hematologic Malignancies
May 2016, Vol 7, No 4
Read Article
Decision Aids: Facilitating Communication with Cancer Survivors
Chase Doyle
Survivorship
,
Policies & Guidelines
May 2016, Vol 7, No 4
Read Article
Multidisciplinary Teamwork Needed for Survivorship Care
Chase Doyle
Survivorship
,
Policies & Guidelines
May 2016, Vol 7, No 4
Read Article
Adverse Events Associated with Tyrosine Kinase Inhibitors Carry High Economic Burden
Chase Doyle
Value in Oncology
May 2016, Vol 7, No 4
Read Article
Impact of Financial Toxicity on Health-Related Quality of Life
Chase Doyle
Value in Oncology
April 2016, Vol 7, No 3
Read Article
Cost of Care Not Linked to Improved Survival for Elderly Patients with Myelodysplastic Syndromes
Chase Doyle
Value in Oncology
April 2016, Vol 7, No 3
Read Article
Improving Survivorship Care: A Patient Advocate's Prescription
Chase Doyle
Survivorship
,
Policies & Guidelines
April 2016, Vol 7, No 3
Read Article
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Read Article
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Read Article
Measuring Value in Healthcare to Improve Quality
Chase Doyle
Economics & Value
,
Value in Oncology
February 2016, Vol 7, No 1
Read Article
Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
Chase Doyle
Value in Oncology
February 2016, Vol 7, No 1
Read Article
Value-Based Purchasing: Implications for Hematology
Chase Doyle
Value in Oncology
,
Value-Based Care
February 2016, Vol 7, No 1
Read Article
Clinical Pathways and the Oncology Medical Home: First Steps to Value-Based Patient Care
Chase Doyle
Clinical Pathways
,
Value in Oncology
February 2016, Vol 7, No 1
Read Article
New Survey: Physicians Are Not Addressing Financial Distress in Patients with Multiple Myeloma
Chase Doyle
Value in Oncology
March 2016, Vol 7, No 2
Read Article
A New Paradigm for Survivorship Care: Assessing the Patient’s Priorities
Chase Doyle
Survivorship
,
Policies & Guidelines
March 2016, Vol 7, No 2
Read Article
Clinical Advances with Targeted Therapies for CLL Also Carry High Economic Burden
Chase Doyle
Value in Oncology
March 2016, Vol 7, No 2
Read Article
Anthem’s Response to Survivorship Medicine: Reimbursement Based on Care Coordination and Patient Outcomes
Chase Doyle
Survivorship
,
Policies & Guidelines
March 2016, Vol 7, No 2
Read Article
Treating Sexual Dysfunction in Breast Cancer Survivors
Chase Doyle
Survivorship
,
Policies & Guidelines
December 2015, Vol 6, No 11
Read Article
Addressing Fertility Issues in Patients with Breast Cancer
Chase Doyle
Survivorship
,
Policies & Guidelines
December 2015, Vol 6, No 11
Read Article
Immunotherapies Steal the Show at ASCO 2015
Chase Doyle
Immunotherapy
,
Personalized Medicine
September 2015, Vol 6, No 8
Read Article
Communication with Oncologists, Not Cost, Tops Patients’ Value Priorities
Chase Doyle
Oncologist–Patient Communication
,
Value in Oncology
,
Value Peer-spectives
September 2015, Vol 6, No 8
Read Article
Value Propositions in Oncology: The Physician Perspective
Chase Doyle
Value in Oncology
,
Value Propositions
,
Value Peer-spectives
July 2015, Vol 6, No 6
Read Article
Anthem’s Clinical Pathways Demonstrate Value: The Payer Perspective
Chase Doyle
Clinical Pathways
,
Value in Oncology
July 2015, Vol 6, No 6
Read Article
The Search for Value-Based Healthcare Delivery: The Agenda for Oncology
Chase Doyle
Value in Oncology
July 2015, Vol 6, No 6
Read Article
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma
Chase Doyle
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Read Article
Choice of Hospital for Readmissions Influences Mortality Risk in Men with Urologic Cancer
Chase Doyle
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Read Article
Insurance Status Impacts Ability to Travel for Care
Chase Doyle
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Read Article
Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with Renal-Cell Carcinoma
Chase Doyle
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Read Article
Regorafenib in Metastatic Colorectal Cancer: High Cost with Little Benefit
Chase Doyle
Economics & Value
,
Economics of Cancer Care
March 2015, Vol 6, No 2
Read Article
Donations
All of our events are free to anyone who may be interested; however, we are accepting donations to offset the cost of the event with any additional proceeds to directly fund the efforts of first responders and front-line healthcare professionals working tirelessly to save lives during this time of national crisis. Tax deductible donations can be made through the AONN+ Foundation for Learning, a 501(c)(3) organization.
Donate Now
Disclaimer:
Funding from these donations to the AONN+ Foundation for Learning will not be used for certification purposes. These funds will solely cover the cost of the event, and all remaining proceeds will be donated to first responders and front-line healthcare professionals. By making a donation you are not entitled to any special benefits; a donation has no direct impact or influence on decisions on certification.
Thank You to Our Webcast Series Supporters
Captain
Captain
Captain
Captain
Captain
Captain
Captain
Captain
Lieutenant
Lieutenant
Lieutenant
Lieutenant
Lieutenant
Lieutenant
Major
Major
Major
Major
View the Latest Issue of VBCC
Read Issue
Podcasts
Clinical Conversations
COVID-19 Webcast Series
Webcast Replays
Webcast Coverage
Faculty
Sponsors
Videos & Articles
About
About AVBCC
Leadership & Co-Chairs
Return to VBCC
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
VBCC
Print Edition
VBCC
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
VBCC
's
Privacy Policy
, and
VBCC
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION